Emcure Pharma IPO: आज 3 July से खुल रहा है Namita Thapar की कंपनी का इश्यू, निवेश से कितना फायदा?
Emcure Pharma IPO Details: एमक्योर फार्मा ने एक्सचेंजों को सूचित किया कि उसने एंकर निवेशकों को 1,008 रुपये प्रति इक्विटी शेयर के हिसाब से 57,79,850 इक्विटी शेयरों के आवंटन को अंतिम रूप दे दिया है। अबू धाबी इनवेस्टमेंट अथॉरिटी, गोल्डमैन सैक्स और मॉर्गन स्टेनली सहित प्रमुख वैश्विक निवेशकों ने एंकर बुक से कंपनी के 71 करोड़ रुपये से अधिक मूल्य के शेयर खरीदे
#emcurepharma #ipo #namitathapar #cnbcawaaz #businessnews #stockmarket #sharemarket #AajKaTajaKhabar #cnbcawaaz #marketnews #latestbusinessnews
n18oc_business
Business News | CNBC Awaaz brings to you latest business news, live share market updates, stock market updates, top business news in india, stock market updates, ipo latest updates, news updates on banking and financials, realty sector and it sector. Watch business news live, business news and share market live updates on CNBC Awaaz. Stay tune to get all the news of pre-opening trades, opening trades, and top calls in pehla sauda. Know what market veterans have to say on the current market trends in big market voices. Watch final trade market strategy, btst stbt calls, intraday strategy and brokerage house calls, quarterly results expectations in kamai ka adda with anuj singhal and virendra kumar. Also stay tune to watch share market tomorrow strategy in kal ka bazaar. Watch CNBC Awaaz and get the best investment ideas.
CNBC Awaaz is one of India’s top business channels and a leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.
Subscribe to the CNBC Awaaz YouTube channel here: [ Ссылка ]
Follow CNBC Awaaz on Twitter: [ Ссылка ]
Like us on our CNBC Awaaz Facebook page: [ Ссылка ]
Website: [ Ссылка ]
